ʻO Combogliz Prolong - kahi lāʻau no ka hanauna hou o ka maʻi maʻi

ʻO ka hui pū ʻana o ka metformin a me DPP4 inhibitors (glyptins) e ʻike ʻia e nā endocrinologists ʻoi loa ka maikaʻi o nā maʻi maʻi 2. ʻO ka waiwai e aʻo ʻia ana mai ka papa o nā gliptins i saxagliptin. ʻO ka pūnaehana o saxagliptin me metformin i hoʻonohonoho ʻia i hoʻokahi papa i kūʻai ʻia ma 2013 ma lalo o ka inoa ʻo Combogliz Prolong.

ʻO nā mea hana i loko o kāna palapala hoʻohālike i ka hopena hoʻohui: hōʻemi lākou i ka pale ʻana i ka insulin a hoʻoikaika i ka synthesis insulin. Eia kekahi, ua hōʻike ka lāʻau lapaʻau i ka palekana no ka puʻuwai a me nā kīʻaha koko, ʻoiaʻiʻo ʻaʻole e hoʻokaumaha i ka hypoglycemia, ʻaʻole ia e kōkua i ka loaʻa ʻana o ka paona. Wahi a nā algorithm maʻi maʻi maʻi ʻĀina e lawe iā Combogliz Prolong no nā mea maʻi me ka nele o ka insulin. Me ka hemoglobin glycated ma luna o 9%, hiki ke hoʻonohonoho koke ʻia ma hope o ka loaʻa ʻana o ka maʻi diabetes.

Ka hana o ka hana a comboglize

ʻO ʻAlogliz Prolong he lāʻau ʻAmelika, ʻo nā kuleana ona nona nā kamupene ʻo Bristol Myers a me Astra Zeneka. Aia nā papa i nā koho dosage 3, kahi e hiki ai ke koho i ka nui o ka metformin a me ka saxagliptin, i pili i nā ʻano o ka maʻi.

ʻO ka maʻi maʻi a me nā hoʻohaʻahaʻa manaʻo e hana ia i ka wā ma mua

• Ka hana maʻamau o ke kō -95%
• Hoʻokuʻuina o ka pua thrombosis - 70%
• Hoʻopau i kahi puʻuwai ikaika -90%
• Hoʻopau i ke kiʻekiʻe o ke koko - 92%
• ʻO ka hoʻonuiʻana i ka ikehu i ka wā, hoʻomaikaʻi i ka hiamoe i ka pō -97%

• 1000 mg + 2.5 mg kūpono ia no nā maʻi maʻi me ka pale ʻana i ka insulin kiʻekiʻe, ka momona, kahi hana haʻahaʻa haʻahaʻa;
• ʻO 1000 mg + 5 mg he koho koho no ka poʻe maʻi me ka maʻi diabetes me ka hoʻēmiʻana i ka synthesis insulin a me kahi momona nui;
• Hoʻohana ʻia ka 500 + 5 mg i ka hoʻomaka ʻana o ka mālama ʻana me Combogliz Prolong, hiki ke hoʻohana ʻia me ka hoʻomau mau ʻia me ka pale lā o ka insulin, ke kaumaha o ke kino maʻamau.

Ke nānā pono nei i ka hoʻohālikelike o Comboglyz a me kāna mau ʻāpana, metformin a me saxagliptin, hoʻohuli ʻia i ʻole ʻike ʻole ʻia i nā pharmacokinetics o nā lāʻau lapaʻau, ka hui ʻana o ʻelua mau mea i loko o kahi papa i hoʻopilikia ʻole i nā waiwai o kekahi o lākou, ua like ka hopena i ka maʻi diabetes.

I ka manawa like, ʻike ʻia kahi hui paʻa paʻa i ka ʻoi aku ka maikaʻi ma mua o ka lawe ʻana i nā lāʻau like ʻole. ʻO kēia ke kumu i ka hoʻonuiʻana i ka pili i ka mālama ʻana, ʻo ia ka ʻōlelo o ka mālama ʻana i nā kauoha a pau a nā kauka. I nā maʻi maʻi, e like me ka diabetes mellitus, he maʻa mau ia: hoʻopoina nā poʻe maʻi e lawe i kekahi kolepa, a ke kāpae nei lākou i ka lawe ʻana i kekahi o nā lāʻau i kuhikuhi ʻia. Hōʻike nā haʻawina i ka maʻalahi o ka hoʻoponopono regimen, ʻoi aku ka maikaʻi o ke kauka. ʻO ka hoʻololi mai ka metformin a me saxagliptin hoʻokaʻawale iā Combogliz Prolong e hiki iā ʻoe ke hoʻomau hou i ka hemoglobin glycated e ka 0.53%.

Metformin

No nā makahiki he nui, he metformin e hānō ʻia e nā hui maʻi maʻi e kuhikuhi i ka hana mua. ʻO kēia ma muli o ke kumu i hana ai nā metformin i ke kumu nui o ka hyperglycemia i nā maʻi maʻi maʻi diabetes 2. Wahi a nā ʻōlelo kuhikuhi, e hōʻemi ʻia ka glycemia i ka maʻi diabetes ma muli o:

• ke kāohi ʻana i ka hana glucose i loko o ke kino (gluconeogenesis, i kahi liʻiliʻi iki - glycogenolysis);
• e hoʻolohi ana i ka hāʻawi ʻana mai o nā honi i loko o kahi pānaʻi;
• hoʻonui i ka hana o ka insulin i nā kiko, ʻoi aku ka ikaika.

ʻO ka hoʻohana ponoʻana o ka lāʻau hoʻohaʻahaʻa i ke kōpaʻa e nānā pinepine ʻia e ka hāʻule o ka hemoglobin glycated i ka wā e lawe ʻia ai. No ka metformin, kiʻekiʻe loa kēia hōʻailona - 1-2%. He kūleʻa ka lāʻau lapaʻau e pili ana i ke kaumaha; ma luna o 10 mau makahiki o ka hoʻokele ʻana, ʻo ka nui o ka hoʻonui ʻana i nā mea maʻi me ka maʻi diabetes he 1 kg, ʻoi aku ka liʻiliʻi ma o ka maʻi maʻi me ka derivatives a me ka sulfonylurea.

ʻO ka mea pōʻino, ʻaʻole hiki ke mau ʻia ka mālama ʻana me ka metformin ma muli o kāna mau hopena ʻeha - hōʻeha o ka ʻōpū, ka ʻōpū, ka maʻi kakahiaka. No ka hoʻomaikaʻi ʻana i ka hoʻomanawanui o ka lāʻau lapaʻau, hoʻomaka ia e hoʻokuʻu i ke ʻano o nā papa me ka hoʻoiho ʻia (hoʻonui) ʻana. ʻO ia kahi metformin e loaʻa ana i Comboglize Prolong. Aia ka papa hana i kahi ʻano kūikawā: ua hoʻokomo ʻia ka mea hana ma ka matrix e hoʻokaʻawale i ka wai. Ma hope o ka lawelawe ʻana, ua lilo ka maka o ka maka i ke kala, kahi e hiki ai i ke kahe o ke metformin lohi i loko o ia koko. Hoʻonui ʻia ka hoʻohaʻahaʻa hilahila i kēia ala a hiki i 24 mau hola, no laila ke hōʻike ʻia nei nā ʻōkuhi no ka hoʻohana ʻana i ka papa lawe ʻana i nā papa i hoʻokahi lā.

Saxagliptin

ʻO kēia māhele o Comboglize Prolong ke kuleana no ka hoʻomaikaʻi ʻana i ka synthesis o ka insulin. ʻO ke kaana o ka hana o ka saxagliptin ka pale ʻana i ka enzyme DPP-4, ʻo ke kuleana o ia ka haʻihaʻi o nā incretins. Hoʻohui ʻia ka nui o ka incretins me ka hoʻonui ʻana i ka glycemia a hoʻonui i ka hoʻonui i ka hana o ka insulin endogenous. Inā hoʻolohi ʻoe i ka hopena o DPP-4, e lōʻihi ka hana ʻana o ka incretins, e hoʻonui ka synthesis o ka insulin, e hoʻēmi ana ka glucose koko.

ʻO ka maikaʻi o ka lāʻau lapaʻau ka pilina o ka glucose i ka hoʻoliʻi koko a me ka hana insulin. ʻAʻohe o nā pilina kumulima o ka sulfonylurea. ʻOiai i nā koina kiʻekiʻe, ʻaʻole hiki i ka saxagliptin ke hoʻonui i ke ola o ka incretins ma mua o 2 mau manawa, no laila ke kaupalena ʻia ka hopena o ke kōpana ma ka manawa a me ka hana ʻole ʻaʻole kumu hypoglycemia. ʻAʻole i hōʻemi ʻia kahi emi weliweli i ka glucose i ka wā o kona hoʻohana ʻana. ʻO ka mālama pono ʻana o ka saxagliptin i nā cell beta e hana ana i ka insulin e hoʻolōʻihi i kā lākou hana a ke kali nei i ka wae ʻana o ka maʻi insulin, kahi hiki ʻole i ka diabetes mellitus.

Ua hoʻolōʻihi nā metformin a me saxacgliptin i ka hoʻolei ʻana i ka glucose mai ka gastrointestinal tract i loko o nā moku. Wahi a nā maʻi maʻi, ʻo nā lāʻau ʻelua e hoʻemi i ka makemake a hoʻolaʻa i ka satiety, no laila ʻo Combogliz Prolong kahi koho maikaʻi loa no nā poʻe maʻi me ka kaumaha nui, ma kahi o nā hui kaulana o ka metformin me ka sulfonylurea.

ʻO kahi wale nō o ka saxagliptin kona kumukūʻai, ʻo ia kahi kauoha e hoʻonui ai i ke kiʻekiʻe ma mua o ka hoʻomākaukau ʻana o nā haʻalulu sulfonylurea.

Nā mea kōkua

Ma kahi o nā mea hana ikaika, loaʻa nō hoʻi i nā papa o Combogliz Prolong nā kumuhana hou e hoʻoikaika i ka hana ʻana a hoʻolako i kahi kuʻuna o ka metformin ka lōʻihi. E like me ka ʻāpana o loko, a i ka matrix, magnesium stearate, hypromellose, carmellose. ʻEkolu papa papa ʻaina i loko o nā papa Opadrai, nona ka talc, titanium oxide, macrogol. ʻO ka papakū luna e loaʻa i kahi waʻa - iron oxide.

Nā ʻokoʻa like ʻole nā ​​ʻāpana like ʻole: 2.5 + 1000 mg melemele, 5 + 500 beige, 5 + 1000 pink. No kēlā me kēia papa pākuʻi, pili ʻia ka dosage kūpono me ka pena polū.

Hoʻokomo ʻia nā mea kōkua me ka feces i ke ʻano hanalulu, hiki ke hana i ke ʻano o kahi pākaukau. ʻAʻohe mea huahana hou loa i kēia pā.

ʻO 3 mau makahiki kahi e noho ai ke ola o nā puʻukū ʻo Comboglize Prolong. ʻO ka pono o ka mea hana no nā kūlana hoʻomalu a hiki i nā kiʻekiʻe 30.

ʻO ke kumu kūʻai o ka pauka mai 3150 a 3900 mau rubles. helu ana ma ka helu o nā papa i loko o kahi pā (28 a 56 mau pcs.) a me ka lihue.

Nā rula no ka lawe ʻana i ka lāʻau

ʻO ka maʻi kau i kēlā me kēia lā o ka saxagliptin no ka hapa nui o nā maʻi maʻi he 5 mg. Ua kuhikuhi ʻia kahi liʻiliʻi liʻiliʻi ʻo 2.5 mg no ka hiki ʻole o ka hana me ka GFR i emi iho ma mua o 50, a me ka lawe ʻana i kekahi mau lāʻau antifungal, antibacterial a me nā antiretroviral e hoʻonui ai i ka paʻa o ka saxagliptin i ke koko.

Koho ʻia ka nui o ke ʻano o ka metformin kūlike i ka pae ʻana o ka kūleʻa o ka insulin. No ka hapalua o ka malama mua, nā mea maʻi me ka inu ʻa ka maʻi ʻa ka papa 1 me ka papaʻa + 5 + 500 mg.

I ka hoʻomakaʻana o ka hoʻōla, ʻoi aku ka kiʻekiʻe o ka hopena o nā mea kūpono i ka metformin. E hōʻemi iā lākou, e lawe paʻa ʻia ka lāʻau me ka meaʻai, ʻoi aku ka maikaʻi i ke ahiahi. Inā hoʻomanawanui maikaʻi ka metformin, ma hope o 2 mau pule, ua hoʻonui ʻia kona nui i ka 1000 mg. Ua inu ʻia ke Saxagliptin ma ke ʻano like like. Inā loaʻa kahi ʻano leʻaleʻa ma ka huina o ke aʻi, pono e hoʻihoʻi i ka nui a hāʻawi ʻia nā manawa hou i ke kino e hoʻomaʻamaʻa ʻia i ka lāʻau lapaʻau. Inā maʻamau ka glycemia, hiki ke lawe ʻia ʻo Combogliz Prolong i loko o kēia kaena like no kekahi mau makahiki me ka ʻole o ka lilo o ka hana pono.

ʻO ka palena kiʻekiʻe loa o Comboglize he 5 + 2000 mg. Hāʻawi ʻia ia e 2 papa o 2.5 + 1000 mg, ʻona lākou ma ka manawa like. Inā ʻaʻole lawa ka 2000 mg o ka metformin no ka maʻi diabetes, hiki ke hoʻokaʻawale ʻia kekahi 1000 mg kaawale, ʻoi aku ka maikaʻi ma kahi o ka manawa lōʻihi (Glucofage Long a me nā analogues: Formin Long, Metformin MV, etc.).

No ka hōʻoia pono ʻana i nā hana like ʻole o nā mea ikaika, ʻoluʻolu ke inu i ka lāʻau ma ia manawa like. No ka mālama ʻana i nā mea i lōʻihi loa i nā papa ʻaʻole hiki ke haki.

Pehea e hoʻohuli ai iā Combogliz Prolong

Ua hemo nā Generics ma Combogliz Prolong a ʻaʻole lākou e ʻike i ka wā e hiki mai ana, ʻoiai ua uhi ʻia ka patent e ka lāʻau. Nā hui hui o nā gliptins linagliptin (kahi hui me ka metformin i hana ʻia ma lalo o ka ʻōlelo kālepa Gentadueto), vildagliptin (Galvus Met hui pū me ka wai), sitagliptin (Velmetia, Yanumet). Ma muli o kā lākou hopena i ka mellitus diō i kokoke loa i ka saxagliptin, akā, ʻokoʻa nā mea kanu i ke ʻano i ka dosage, pharmacokinetics, contraindications, no laila pono ke kūleʻa ka loli i kahi lāʻau hou.

Pehea e hiki ai iā ʻoe ke mālama ma ke kūʻai aku o Combogliz Prolong:

1. "E hōʻiliʻili" ʻo Combogliz Prolong mai Onglisa a me Metformin. Onglisa - kahi lāʻau lapaʻau o nā mea hana like, loaʻa he 2.5 a 5 mg o ka saxagliptin. ʻO kona kumu he 1800 mau rubles. no nā papa 30 o 5 mg. I mea e hoʻopau hou ai i ka hoʻopili ʻana o Combogliz Prolong, hoʻohui ʻia kekahi metformin lōʻihi i Ongliz, e uku ʻia ana ʻo 250-750 rubles i hoʻokahi mahina.
2. E noi i kāu kauka i kahi lāʻau lapaʻau manuahi no ka saxagliptin. ʻAʻole loaʻa paha ka lāʻau i nā wahi a pau, akā e ulu nei kā lākou helu i kēlā me kēia makahiki. Hōʻike hōʻailona no ka koho saxagliptin - pinepine pinepine a hypoglycemia ma sulfonylurea. No ka mea ʻole nā ​​lāʻau lapaʻau i nā mea kūʻai aku maʻalahi, e hāʻawi ka lāʻau lapaʻau iā ʻoe nā pilia ʻo Combogliz Prolong, a i ʻole nā ​​metformin a me Onglizu.
3. Inā ʻoe e kauoha i ka lāʻau i loko o kahi lāʻau lapaʻau pūnaewele a koho iā ʻoe iho mai kahi o ke kumu o ka hoʻopuka ʻana, hiki iā ʻoe ke mālama e pili ana i 10% o kāna kumukūʻai.

Ke hoʻololi nei i nā derivatives sulfonylurea no ka hikiʻole, no ka mea hiki iā lākou ke hōʻeha i ka hypoglycemia. Ināʻaʻohe ala ʻē aʻe, ʻoi aku ka maikaʻi e lawe i ka glimepiride palekana a me ka gliclazide. Nā manaʻo o ka lāʻau Combogliz me kēia mau mea - Amaril M, Glimecomb.

Nā hōʻailona no ka hoʻohana ʻana

Wahi a nā ʻōkuhi, ua hoʻohālikelike ʻia nā papa ʻo Combogliz Prolong no ka maʻi maʻamau o ka lā 2, inā ʻaʻole ke hōʻemi ka hoʻoponopono ʻana i ka mea pono a me ka hana kino. Hāʻawi ʻia i ke kumukūʻai kiʻekiʻe o ka lāʻau lapaʻau, ʻano palupalu kona kikoʻe. Wahi a nā endocrinologists, kākau lākou i ka lāʻau i loko o kēia mau hihia:

1. Inā ua hōʻemi ʻia ka mea maʻi i ka synthesis o ka insulin, a ua lawe aku i ka sulfonylurea.
2. Me ka hopena kiʻekiʻe o ka hypoglycemia: ka mea elemakule, maʻi pākē me nā maʻi concomitant a me nā mea kauʻai meaʻai, nā mea maʻi me ke kiʻekiʻe o ka hana kino, hana ʻia i ka hana e koi ai i ka manaʻo nui.
3. ʻO nā maʻi maʻi maʻi ka poʻe ʻaʻole e mālama ʻole i nā ʻōlelo a ke kauka e hoʻopoina e lawe i kahi paena a ʻai paha i ka manawa.
4. ʻO ka maʻi maʻamau me ka neuropathy nāna i holoi i nā hōʻailona o ka hypoglycemia.
5. Inā kuhi ka maʻi maʻi maʻi me kona ikaika a pau e pale aku i ka loli ʻana i ka insulin. Ke manaʻoʻiʻo ia hiki ke hoʻokaʻawale ka sulfonylurea i ka luku ʻana i nā poli beta. ʻAʻohe ʻikepili e pili ana i ka sacasagliptin.

Nā Hoʻohui

ʻO ka papa inoa o nā contraindications i nā ʻōlelo kikoʻī no Combogliz Prolong e ākea loa, e like me ia i loko o kekahi lāʻau lapaʻau hoʻohui.

Nā hopena hopena

Hoʻonui iki ʻo Saxagliptin i ka hōʻemi o ka ʻeha (ma ka 1.5%), sinusitis, helehelena (1%), ʻeha o ka ʻōpū (1.9%), gastroenteritis (1,4%), kahi hopena alakanui (1.1%).

ʻO nā hopena e hōʻike ana i ka hopena o ka metformin, nausea a me ka luaʻi i ʻike ʻia i ka wā e lawe ai i nā papa ʻo Combogliz Prolong. ʻO kā lākou pinepine ma mua o 5%.

ʻO ka overdose o ka saxagliptin ʻaʻole ia i pōʻino a hoʻoiho i ka inu. Ke puka i kahi kaʻe o ka metformin hiki ke pili pono i ke olakino. ʻO kahi hapakolu o nā maʻi maʻi maʻi i lawe a ʻoi aku ma mua o 50 g o ka metformin i hoʻokahi manawa hoʻomaka i hoʻomohala i ka acidosis lactic.

ʻOiai e lawe ana i ka Metformin Prolong, hiki i kekahi mau lāʻau ke loli i ka hopena hypoglycemic. Pono ka nānā pono ʻana i nā antibiotika, antifungal, hormonal a me nā lāʻau antihypertensive, antidepressants, kā lākou papa helu piha i loko o nā kauoha. I ka hoʻohana ʻana i ka ketoconazole antifungal a me itraconazole, ʻae ʻia nā antibiotika clarithromycin a me telithromycin, nā antioepresant a ʻozodone, nā lāʻau anti-HIV i kēlā lā i kēia lā, ʻo 2.5 mg wale nō o ka saxagliptin e ʻae ʻia.

Nā Hōʻikeʻike e pili ana iā Comboglize